IGF-1 LR3 1mg
A long-acting synthetic analog of IGF-1 engineered for enhanced half-life and potent anabolic signaling in laboratory models.
Mechanism
IGF-1 LR3 binds directly to the tyrosine kinase IGF-1 receptor with negligible interference from inhibitory IGFBPs, triggering downstream Akt and MAPK signaling cascades that govern protein synthesis and cellular replication.
Dosing
Reference protocols document an initial daily research dose of 20 mcg administered subcutaneously, which may be gradually escalated based on tolerance.
Reconstitution
Reconstituting a 1 mg vial with 3.0 mL of bacteriostatic water yields an operational working solution of approximately 0.333 mg/mL (333 mcg/mL).
Storage
Preserve unmixed lyophilized vials at or below -20°C shielded from light, and store the reconstituted liquid solution at 2–8°C for up to 30 days without re-freezing.
Mix & measure IGF-1 LR3 1mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure IGF-1 LR3 1mg
Vial strength → BAC water → target dose
Common vial sizes
Label claim
Total doses in vial: 50.0
U-100 syringe: 100 units = 1 mL
Need supplies for this protocol?
Research-grade peptides, fast shipping, competitive pricing
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Track my protocol
Log each dose, build a streak, and watch your progress through this protocol's schedule.
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–2 | 20 mcg (1× daily) | ~6 units (0.06 mL) |
| Weeks 3–4 | 40 mcg (1× daily) | ~12 units (0.12 mL) |
| Weeks 5–8 | 50 mcg (1× daily) | ~15 units (0.15 mL) |
Reconstitution Steps
- 1
Draw exactly 3.0 mL of bacteriostatic water into a sterile syringe.
- 2
Introduce the liquid slowly down the interior glass wall of the IGF-1 LR3 vial to minimize agitation and foaming.
- 3
Gently rotate and roll the container between the palms until the lyophilized cake is fully dissolved, strictly avoiding vigorous shaking.
- 4
Document the reconstitution date and calculated concentration on the vial label, then immediately refrigerate at 2–8°C.
Supplies Needed
Peptide Vial
1 mg vial of lyophilized IGF-1 LR3 for laboratory evaluation.
Insulin Syringes (U-100)
0.5 mL or 1.0 mL U-100 syringes utilized for accurate micro-volume measuring and administration.
Bacteriostatic Water
3.0 mL of sterile preserved diluent per vial for reconstitution.
Alcohol Swabs
Antiseptic wipes to disinfect vial stoppers and experimental injection zones.
Why researchers study it
Muscle growth & anabolism
Tissue repair & recovery
Cell hyperplasia & GH/IGF-1 axis
Fat metabolism & nutrient partitioning
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
IGF-1 LR3 (Long-Arg3 Insulin-like Growth Factor-1) is a synthetic derivative of natural insulin-like growth factor-1 featuring an added 13-amino-acid N-terminal sequence alongside an arginine substitution at residue 3. These structural modifications drastically weaken its affinity for endogenous IGF-binding proteins (IGFBPs). Consequently, the analog demonstrates an extended circulatory clearance window and vastly elevated biological bioavailability in cell cultures and test models compared to the native hormone. In experimental models, IGF-1 LR3 is principally researched for its capacity to stimulate systemic protein accretion, satellite cell proliferation, and nutrient partitioning. Because it mimics insulin-mediated pathways to facilitate glucose uptake, investigations monitor strict glycemic thresholds throughout titration phases. The compound remains strictly a non-clinical, investigational chemical limited to laboratory research and cellular signaling studies.
References
- 1.Growth Hormone & IGF Research, 1999 — Long-Arg3-IGF-1: structure, reduced IGF binding-protein affinity, and extended biological activity of the analog
- 2.Journal of Biological Chemistry, 1990 — Reduced binding-protein affinity and enhanced potency of N-terminally extended IGF-1 analogs
- 3.StatPearls / NCBI, 2023 — Recognition and management of hypoglycemia, including symptoms and rapid-carbohydrate treatment
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.
Related protocols
View allIGF-1 DES 1mg
A truncated, high-affinity IGF-1 variant lacking three N-terminal residues, investigated for potent localized cellular hypertrophy.
View ProtocolPemvidutide 5mg
Investigational GLP-1/glucagon dual agonist evaluated in clinical models for targeted hepatic fat clearance and metabolic regulation.
View ProtocolPNC-27 30mg
Preclinical chimeric peptide targeting HDM-2 on cell membranes, investigated for membrane-lytic activity in oncological models.
View Protocol